We are live on ! Find out more
PTCT icon

PTC Therapeutics
PTCT

99 hedge funds and large institutions have $1.07B invested in PTC Therapeutics in 2014 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 23 increasing their positions, 26 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

83% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 18

78% more capital invested

Capital invested by funds: $601M → $1.07B (+$471M)

18% more funds holding

Funds holding: 84 → 99 (+15)

12% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 26

Holders
99
Holders Change
+15
Holders Change %
+17.86%
% of All Funds
2.87%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
33
Increased
23
Reduced
26
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$25.6M
2
TAM
Tocqueville Asset Management
New York
+$9.37M
3
UBS AM
UBS AM
Illinois
+$8.56M
4
Citadel Advisors
Citadel Advisors
Florida
+$7.46M
5
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$7.28M

Top Sellers

Rank Fund Capital Flow
1
CS
Credit Suisse
Switzerland
-$22.2M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$7.16M
3
NI
Numeric Investors
Massachusetts
-$6.79M
4
O
OrbiMed
New York
-$4.66M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
Point72 Asset Management
26
Point72 Asset Management
Connecticut
$6.89M +$4.9M +156,500 New
CNB
27
City National Bank
California
$6.83M +$264K +8,434 +6%
Lord, Abbett & Co
28
Lord, Abbett & Co
New Jersey
$6.72M +$4.77M +152,607 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$6.26M +$56.2K +1,796 +1%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$5.72M +$66.4K +2,122 +2%
CAM
31
Cormorant Asset Management
Massachusetts
$5.5M -$782K -25,000 -17%
Deutsche Bank
32
Deutsche Bank
Germany
$5.43M +$2.05M +65,588 +113%
MLICM
33
Metropolitan Life Insurance Company (MetLife)
New York
$5.29M +$3.21M +102,746 +587%
Invesco
34
Invesco
Georgia
$4.98M +$1.05M +33,663 +42%
TCIM
35
TIAA CREF Investment Management
New York
$4.33M -$39.7K -1,268 -1%
Asset Management One
36
Asset Management One
Japan
$4.25M +$2.92M +93,279 New
USAA
37
United Services Automobile Association
Texas
$4.05M – – –
TCM
38
Tekla Capital Management
Massachusetts
$3.48M – – –
PAMU
39
Pictet Asset Management (UK)
United Kingdom
$3.45M -$141K -4,500 -5%
EI
40
EAM Investors
California
$3.06M -$1.24M -39,790 -36%
JP Morgan Chase
41
JP Morgan Chase
New York
$2.99M +$2.12M +67,864 New
BIM
42
BlackRock Investment Management
Delaware
$2.88M +$18.3K +585 +0.9%
SFM
43
Sphera Funds Management
Israel
$2.8M -$2.7M -86,375 -58%
Axa
44
Axa
France
$2.72M – – –
Charles Schwab
45
Charles Schwab
California
$2.57M +$253K +8,093 +16%
MSA
46
Mason Street Advisors
Wisconsin
$2.5M +$1.78M +56,810 New
RFC
47
Russell Frank Company
Washington
$2.34M -$936K -29,933 -36%
TA
48
Teachers Advisors
New York
$2.2M +$586K +18,746 +60%
RA
49
Royce & Associates
New York
$2.2M – – –
GTC
50
Ghost Tree Capital
New York
$2.2M +$1.56M +50,000 New
1
2
3 4 5

PTCT Hedge Fund Activity: Q3 2014 in Review

99 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2014, worth a combined $1.07B — up 78% from $601M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new PTCT positions and 18 closed out — a net gain of 15 holders — while 23 added to existing stakes and 26 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $25.6M. The largest seller was Credit Suisse, cutting an estimated $22.2M.

  • 99 institutional investors held PTC Therapeutics (PTCT) as of Q3 2014, up from 84 in Q2 2014.
  • Funds reported $1.07B of PTC Therapeutics stock for Q3 2014, up 78% quarter-over-quarter.
  • 33 funds opened new PTC Therapeutics positions in Q3 2014 and 18 closed out, a net change of +15 holders.
  • The largest PTC Therapeutics buyer in Q3 2014 was Wellington Management Group, an estimated $25.6M added.
  • The largest PTC Therapeutics seller in Q3 2014 was Credit Suisse, an estimated $22.2M sold.

Based on aggregated 13F filings for Q3 2014.